FDA Opens a New Therapeutic Path for Adults With Recurrent Respiratory Papillomatosis
The U.S. Food and Drug Administration granted accelerated approval to Voceryq for adults with recurrent respiratory papillomatosis, a rare HPV-driven disease that repeatedly seeds wart-like growths in the airway. The approval is the first in the U.S. for a plasmid DNA-based immunotherapy, and it arrives in a condition where surgery has long been the central, repetitive, and often exhausting treatment strategy.
Adults with recurrent respiratory papillomatosis live with disease that does not simply disappear after a procedure. HPV types 6 and 11 persist in the tissue, so the papillomas can return again and again, most often around the larynx and vocal cords. Hoarseness, chronic cough, and voice change are common; in more severe cases, the growths can extend deeper into the respiratory tract and interfere with breathing. Over time, repeated operative removal becomes part of the disease experience, and a subset of patients also faces malignant potential.
For that reason, a therapy built to redirect immune recognition toward the underlying viral driver carries real clinical weight. Voceryq combines two plasmids: one delivers genetic instructions for HPV proteins, and the other encodes IL-12, an immune response-enhancing molecule. The treatment is designed to stimulate the body to recognize and attack cells infected by the specific HPV types linked to RRP. Rather than simply shaving away visible lesions, the biologic strategy aims at the virus-associated machinery that keeps the disease returning.
The delivery system is part of the biology. Voceryq is administered by intramuscular injection with the CELLECTRA 5PSP Device, which uses electroporation to briefly and reversibly open cell membranes so the plasmid DNA can enter cells. In practical terms, the platform is doing more than placing a drug into muscle; it is trying to improve cellular uptake of genetic material and amplify local antigen presentation, a necessary step if the immune system is going to mount a more useful response against HPV-infected tissue.
Trial Signals Centered on Fewer Surgeries
The FDA’s accelerated approval rested on clinical trial data from an open-label multicenter study of 32 adults with RRP. Eligible patients had at least two surgeries to remove laryngotracheal papillomas during the 12 months before treatment, including a scheduled surgery at trial entry. In a disease where operative recurrence is the day-to-day problem, a fall in surgical frequency is not a cosmetic endpoint. It is the outcome that changes clinic burden, anesthesia exposure, and the rhythm of a patient’s life.
Among the 26 patients who had at least three baseline surgeries, seven patients — 27% — did not require any surgical intervention during the first year after treatment. That finding is the central clinical signal supporting the approval. The agency classified reduced surgery frequency as an intermediate endpoint reasonably likely to predict benefit, and the manufacturer must now conduct post-approval studies to verify and describe Voceryq’s clinical effect more fully.
The study design leaves some questions open, as open-label trials often do. Without masking, expectations from both patients and investigators can influence clinical decision-making, particularly in a disease where surgery timing may vary from one patient to another. Still, the basic direction of the data is clinically meaningful: for a subset of adults who entered the study with a heavy surgical burden, the need for repeat procedures fell to zero over the first year.
Safety Profile Reflects Both the Product and the Delivery Device
Safety observations in the trial were consistent with a therapy delivered through both injection and electroporation. The most common adverse reactions were injection site reactions, headache, fatigue, hypertension, nausea, and dizziness. Those events matter because they frame how the therapy may be experienced in routine care, especially for adults already coping with chronic airway disease and repeated procedures.
Electroporation adds its own adverse-effect profile. Brief muscle contractions or tetany, temporary bleeding at the administration site, anxiety, vasovagal reactions including lightheadedness and dizziness, transient creatine phosphokinase changes, erythema at the injection site, and pain at the administration site may occur. The device is not a passive accessory; it is part of the treatment mechanism, and its tolerability will influence uptake in real-world practice.
The approval also carries Breakthrough Therapy and Orphan Drug designations, a regulatory reflection of both the unmet need and the biologic rationale behind the product. For a rare disease with no cure and a long history of recurrence after surgery, even a modest reduction in procedures can alter care patterns in a meaningful way. Fewer trips to the operating room may also reduce cumulative procedural risk, lessen disruptions to work and family life, and ease the constant uncertainty that tends to define chronic airway papillomatosis.
Why the FDA Pathway Matters for a Rare Airway Disease
Accelerated approval exists for serious or life-threatening diseases when a surrogate or intermediate clinical endpoint is reasonably likely to predict benefit. In recurrent respiratory papillomatosis, that logic is straightforward: if a therapy reduces the need for surgery in a disease defined by repeated regrowth, it may be interrupting the cycle that drives disability. The regulatory pathway, however, also places the burden of proof forward in time. Confirmatory studies must still define the magnitude, durability, and broader clinical relevance of benefit.
This matters because airway papillomatosis is not just a lesion problem; it is a chronic viral persistence problem. Surgery clears tissue, but it does not eradicate the pathogen from the host environment. A plasmid DNA-based immunotherapy attempts to shift that balance by mobilizing host immunity against HPV 6 and 11, and that mechanism is biologically plausible in a condition where immune evasion likely helps sustain recurrence.
Vocyryq’s approval also marks the first U.S. authorization for a plasmid DNA-based immunotherapy, which gives the decision significance beyond one disease category. The platform itself will be watched closely, not only for recurrent respiratory papillomatosis but as a test of whether genetic immunotherapy can produce durable disease modification in other HPV-related settings.
The immediate unanswered issue is durability. One year without surgery in a subset of patients is encouraging, but chronic viral disease rarely yields all its answers quickly, and the post-approval trials will need to show whether the benefit persists, which patients are most likely to respond, and how the safety profile looks with broader use over time.